ESMO Asia 2016 Congress

Oncology Meeting Resources

16 Dec - 19 Dec 2016, Singapore

ESMO Asia 2016 Square

The ESMO Asia Congress comprised both scientific and educational tracks prepared by an international scientific committee. There was a strong emphasis on state of the art science, including a call for abstracts, and the current standard of care across all major tumour types.

Abstracts, presentations and webcasts from the ESMO Asia 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...ntracellular-AKT-mTOR-pathway-in-tumor-cells

BackgroundProgrammed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) engagement usually leads to diminished antitumor T-cell responses, which mediates the immune escape of tumor cells.

Date: 19 Dec 2016
Presenter: Huilai Zhang
Resources: Abstract
Topics: Lymphomas, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...ion-outcome-in-diffuse-large-B-cell-lymphoma

BackgroundThe predictive value of 18F-FDG PET in patients with diffuse large B cell lymphoma (DLBCL) who are receiving high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT) remains a matter of debate.

Date: 19 Dec 2016
Presenter: Zhitao Ying
Resources: Abstract
Topics: Lymphomas, Imaging, Diagnosis and Staging

http://oncologypro.esmo.org/Meeting-Resourc...s-in-chronic-myeloid-leukemia-Lest-we-forget

BackgroundClonal cytogenetic evolution with additional cytogenetic aberrations (ACAs) in chronic myeloid leukemia (CML) are associated with adverse prognosis and decreased response to tyrosine kinase inhibitor therapy (TKI).

Date: 19 Dec 2016
Presenter: Madhav Danthala
Resources: Abstract
Topics: Leukaemia, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...ve-resection-of-metastatic-colorectal-cancer

BackgroundLymph node (LN) status is one of the most important predictors for M0 colorectal cancer patients. However, its clinical impact on stage IV colorectal cancer remains unclear.

Date: 19 Dec 2016
Presenter: Qingguo Li
Resources: Abstract
Topics: Colon Cancer, Rectal Cancer, Pathology/Molecular Biology, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...e-metastases-in-submucosal-colorectal-cancer

BackgroundIn colorectal cancer (CRC), the possibility of lymph node (LN) metastases is important to select the treatment. According to the Japanese Society for Cancer of the Colon and Rectum guidelines...

Date: 19 Dec 2016
Presenter: Shiki Fujino
Resources: Abstract
Topics: Colon Cancer, Rectal Cancer, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...nalysis-of-the-phase-1-2-CheckMate-040-study

BackgroundMedian overall survival (OS) for first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC) with sorafenib (sor) is up to 11 mo and 7–8 mo with best supportive care (BSC) post-sor failure.

Date: 19 Dec 2016
Presenter: Ignacio Melero
Resources: Abstract
Topics: Hepatobiliary Cancers, Cancer Immunology and Immunotherapy

http://oncologypro.esmo.org/Meeting-Resourc...ine-therapy-in-advanced-gastric-and-gastroes

BackgroundClaudin(CLDN)18.2 is a stomach specific tight junction protein. The chimeric monoclonal anti-CLDN18.2 antibody IMAB362 potently activates complement and antibody dependent cellular cytotoxicity.

Date: 19 Dec 2016
Presenter: Florian Lordick
Resources: Abstract
Topics: Drug Development, Gastric Cancer